[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350047-105":59,"doc-detail-350047-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","mechanism-of-il-4-mediated-rpl19-promoting-malignant-progression-in-her2-positive-breast-cancer-research-open-access","Mechanism of IL-4 mediated RPL19 promoting malignant progression in HER2 positive breast cancer - Research Open Access","","Breast cancer remains the leading cause of cancer-related mortality in women worldwide, with survival varying by subtype. HER2 is amplified in about 25% of primary breast cancers and drives aggressive disease and poor prognosis. Although HER2-targeted therapies like trastuzumab can produce durable responses, resistance is common. RPL19 is coexpressed with HER2 and promotes malignant progression through IL-4 signaling, influencing tumor growth, metastasis, trastuzumab sensitivity, and macrophage-mediated phagocytosis.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/mechanism-of-il-4-mediated-rpl19-promoting-malignant-progression-in-her2-positive-breast-cancer-research-open-access/350047/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/mechanism-of-il-4-mediated-rpl19-promoting-malignant-progression-in-her2-positive-breast-cancer-research-open-access/350047.png","ImageObject",300,407,{"name":92,"@type":93},"Connor ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-11","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What role does RPL19 play in HER2-amplified breast cancer?","Question",{"text":112,"@type":113},"RPL19 is overexpressed in HER2-amplified breast cancer and promotes tumor growth and metastasis while reducing sensitivity to trastuzumab.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does RPL19 regulate IL-4 and downstream signaling?",{"text":117,"@type":113},"RPL19 upregulates IL-4 via the transcription factor JUN, activating IL-4/p-STAT6 signaling and supporting malignant progression.",{"name":119,"@type":110,"acceptedAnswer":120},"How does IL-4 affect macrophage phagocytosis in the tumor microenvironment?",{"text":121,"@type":113},"RPL19 inhibits macrophage-mediated phagocytosis of tumor cells by regulating IL-4 secretion, thereby further promoting tumor progression.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},350047,1790193360,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},687207022233,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Zhang et al. Breast Cancer Research (2026) 28:65 Breast Cancer Research  \n[https://doi.org/10.1186/s13058-026-02240-9](https://doi.org/10.1186/s13058-026-02240-9)  \nRESEARCH Open Access  \nMechanism of IL-4 mediated RPL19 promoting  malignant progression in HER2 positive breast cancer  \nNana Zhang1†, Jian Zhang2†, Junchao Shao3†, Zhenfeng Huang3, Jinxing Zhang3, Hao Wang3, Liangshuang Lv3, Zibo Shen4, Peng Zhang5, Bing Liu6*, Guoqiang Zhang3* and Ming Shan3*  \nAbstract  \nBackground Despite recent improvements in prognosis, breast cancer remains the leading cause of cancer-related mortality in women worldwide. Survival rates vary across breast cancer subtypes. HER2, an oncogene, is amplified in approximately 25% of primary breast cancers and associated with an aggressive clinical course and a poor prognosis. Although HER2-targeted therapies induce significant and durable responses, resistance remains prevalent. RPL19 is coexpressed and positively correlated with HER2 .  \nMethods Analysis of The Cancer Genome Atlas (TCGA) revealed RPL19 upregulation in HER2-amplified breast cancer. Further validation with paired breast cancer and adjacent normal tissues confirmed the differential expression of RPL19 in HER2-amplified breast cancer. In vitro and in vivo functional assays demonstrated that RPL19 promotes the growth and metastasis of HER2-amplified breast cancer cells. Mechanistically, RPL19 upregulates IL-4 via the transcription factor JUN. RPL19 promotes tumor cell proliferation, migration, and invasion, and reduces their sensitivity to trastuzumab through the IL-4/p-STAT6 signaling pathway. In the tumor microenvironment, RPL19 inhibits macrophage-mediated phagocytosis of tumor cells by regulating IL-4 secretion, further promoting tumor progression.  \nResults In summary, RPL19 is overexpressed in HER2-amplified breast cancer and promotes tumor cell growth, metastasis, and reduces their sensitivity to trastuzumab. Through JUN-mediated regulation of IL-4, RPL19 influences the progression and reduces their sensitivity to trastuzumab of HER2-amplified breast cancer via the IL-4/p-STAT6 signaling and IL-4-mediated macrophage phagocytosis pathways.  \nConclusions These pathways may represent novel therapeutic targets for HER2-amplified breast cancer.  \n†Nana Zhang, Jian Zhang and Junchao Shao have authors contributed equally to this work.  \n*Correspondence:  \nBing Liu [liubingdoctor123@126.com](liubingdoctor123@126.com)[ ](liubingdoctor123@126.com)Guoqiang Zhang [zhangguoqiang@hrbmu.edu.cn](zhangguoqiang@hrbmu.edu.cn)[ ](zhangguoqiang@hrbmu.edu.cn)Ming Shan [shanming@ems.hrbmu.edu.cn](shanming@ems.hrbmu.edu.cn)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.)  \nZhang et al. Breast Cancer Research (2026) 28:65 Page 2 of 21  \nKeywords HER2-amplified breast cancer, Ribosomal proteins, Human ri","cbCaicBjxWtpywF3","https://ap.wps.com/l/cbCaicBjxWtpywF3","pdf",4112033,21,"English","# Abstract\n# Background\n# Methods\n# Results\n# Conclusions\n# Keywords","[{\"question\":\"What role does RPL19 play in HER2-amplified breast cancer?\",\"answer\":\"RPL19 is overexpressed in HER2-amplified breast cancer and promotes tumor growth and metastasis while reducing sensitivity to trastuzumab.\"},{\"question\":\"How does RPL19 regulate IL-4 and downstream signaling?\",\"answer\":\"RPL19 upregulates IL-4 via the transcription factor JUN, activating IL-4/p-STAT6 signaling and supporting malignant progression.\"},{\"question\":\"How does IL-4 affect macrophage phagocytosis in the tumor microenvironment?\",\"answer\":\"RPL19 inhibits macrophage-mediated phagocytosis of tumor cells by regulating IL-4 secretion, thereby further promoting tumor progression.\"}]","Mechanism of IL-4 mediated RPL19 promoting malignant progression in HER2 positive breast cancer - Research Open Access | PDF",1790086905,53,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f6904d2970cf122dcdd4e9e9eb3906a2.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/663934da1c1c23e7ae7e1a50aa4be53e.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e428a2c844c2548ce05c93210c900c6d.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aabb1bf9e1d32140fbec3c34d8012e07.webp",980,1306]